Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma

2004802 citationsJournal Article

Authors

Robert J. Motzer

Jennifer Bacik · Memorial Sloan Kettering Cancer Center

Lawrence H. Schwartz · Memorial Sloan Kettering Cancer Center

Victor E. Reuter · Memorial Sloan Kettering Cancer Center

Paul Russo · Memorial Sloan Kettering Cancer Center

Stéphanie Marion · Memorial Sloan Kettering Cancer Center

Madhu Mazumdar · Memorial Sloan Kettering Cancer Center

Abstract

Treatment with novel agents during a clinical trial is indicated for patients with metastatic RCC after progression to cytokine treatment. Three prognostic factors for predicting survival were used to categorize patients into risk groups. These risk categories can be used in clinical trial design and interpretation.

Topics & Keywords

Renal cell carcinoma treatment Multiple and Secondary Primary Cancers Cancer Genomics and Diagnostics

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 22, Issue 3, pp. 454-463

DOI: 10.1200/jco.2004.06.132

Field-Weighted Citation Impact: 33.39